Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Sihyun | - |
dc.contributor.author | Jung, Ji Ann | - |
dc.contributor.author | Lee, Yousun | - |
dc.contributor.author | Kim, Hye Yeon | - |
dc.contributor.author | Seo, Seok Kyo | - |
dc.contributor.author | Choi, Young Sik | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Lee, Byung Seok | - |
dc.date.available | 2020-02-28T18:43:32Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 0001-6349 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12925 | - |
dc.description.abstract | ObjectiveAlthough the levonorgestrel-releasing intrauterine system (LNG-IUS) is effective in reducing the recurrence of endometriosis-associated pain, its efficacy in preventing endometrioma recurrence is questionable. We compared the efficacy of postoperative use of LNG-IUS with oral contraceptives (OC) for preventing endometrioma recurrence. DesignA retrospective cohort study. SettingMedical university hospital. PopulationNinety-nine women with endometriomas. MethodsA chart review was performed of women of reproductive age who had undergone laparoscopic surgery for endometrioma followed by three cycles of gonadotropin-releasing hormone agonist (leuprolide acetate) treatment. Women were categorized into two groups: a group that had postoperative LNG-IUS placement (n=42) and a group that received postoperative, cyclic, low-dose, monophasic, OCs (n=57). Main outcome measuresEndometrioma recurrence was analyzed according to several clinical variables and postoperative treatment modalities. ResultsDuring the follow-up period (median 17months), recurrent endometriomas were detected in eight women (8.1%). Patients with LNG-IUS had a recurrence rate of 4.8% (2/42), whereas women receiving OC had a recurrence rate of 10.5% (6/57). Cumulative recurrence-free survival assessment revealed that mean disease-free survival times for both groups were similar, but that for LNG-IUS was slightly longer than that for OC, with statistical significance (34.41.0months, 95% confidence interval 32.3-36.5, vs. 33.4 +/- 1.3months, 95% confidence interval 30.8-36.0, p=0.045). Univariate analysis revealed a hazard ratio of 0.178 (95% confidence interval 0.029-1.075) (p=0.060) for postoperative LNG-IUS use and endometrioma recurrence. However, for the multivariate regression analysis, only postoperative serum CA125 levels were significantly associated with endometrioma recurrence (hazard ratio 1.012, p=0.010). ConclusionsPostoperative LNG-IUS use seemed to be comparable to the use of cyclic OC in preventing endometrioma recurrence. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.relation.isPartOf | ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA | - |
dc.subject | 3-YEAR FOLLOW-UP | - |
dc.subject | SYMPTOMATIC ENDOMETRIOSIS | - |
dc.subject | PELVIC PAIN | - |
dc.subject | LAPAROSCOPIC EXCISION | - |
dc.subject | OVARIAN ENDOMETRIOMAS | - |
dc.subject | CONSERVATIVE SURGERY | - |
dc.subject | CONTROLLED-TRIAL | - |
dc.subject | WOMEN | - |
dc.subject | MANAGEMENT | - |
dc.subject | DEVICE | - |
dc.title | Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000328435300006 | - |
dc.identifier.doi | 10.1111/aogs.12294 | - |
dc.identifier.bibliographicCitation | ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, v.93, no.1, pp.38 - 44 | - |
dc.identifier.scopusid | 2-s2.0-84890476801 | - |
dc.citation.endPage | 44 | - |
dc.citation.startPage | 38 | - |
dc.citation.title | ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA | - |
dc.citation.volume | 93 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Lee, Ji Sung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Levonorgestrel-releasing intrauterine system | - |
dc.subject.keywordAuthor | oral contraceptive | - |
dc.subject.keywordAuthor | endometrioma | - |
dc.subject.keywordAuthor | recurrence | - |
dc.subject.keywordAuthor | CA 125 | - |
dc.subject.keywordPlus | 3-YEAR FOLLOW-UP | - |
dc.subject.keywordPlus | SYMPTOMATIC ENDOMETRIOSIS | - |
dc.subject.keywordPlus | PELVIC PAIN | - |
dc.subject.keywordPlus | LAPAROSCOPIC EXCISION | - |
dc.subject.keywordPlus | OVARIAN ENDOMETRIOMAS | - |
dc.subject.keywordPlus | CONSERVATIVE SURGERY | - |
dc.subject.keywordPlus | CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | WOMEN | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | DEVICE | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.